March 19, 2010 /EIN PRESSWIRE/ The relationship between the scientific community and pharmaceutical companies is coming under fire again.

At the center of the most recent black eye is the diabetes drug Avandia. The immensely popular drug was linked with an increased risk of heart attacks in research published in 2007. Since the findings, the scientific community has largely come to the defense of the drug, but a new report suggests a growing concern with conflict of interest between scientists and pharmaceutical companies.

Researchers from the Mayo Clinic analyzed more than 200 articles published after 2007 in scientific journals, which commented on the heart-attack risk associated with Avandia. They found 47% of the study authors had financial conflicts of interest, but 23% of them not disclose it.

The Mayo study says 94% of the authors who had positive views about Avandia had financial links with pharmaceutical companies and 87% had financial links with the drug’s manufacturer, GlaxoSmithKline.

Of the 29 articles strongly recommending the rival Eli Lilly drug, Actos, as a replacement for Avandia, 25 were by authors with financial links to Lilly.

Read more at Pharmaceutical Industry Today:

Avandia news –
Actos news –

Located at, Pharmaceutical Industry Today is a service of EIN News, an industry leader in news monitoring for business professionals and analysts. Using a combination of proprietary search technology and human editing, EIN News delivers to its members the latest pharmaceutical news from around the world, saving them valuable time they’d spend searching for information. New users to Pharmaceutical Industry Today can enjoy a no-obligation, one-week free trial.

About EIN Presswire
The EIN Presswire press release distribution service is a news-syndication solution that distributes news to more than 10 million visitors annually at EIN News and millions more through its press release distribution partners. A news source for leading journalists, decision-makers and industry professionals worldwide, EIN Presswire targets press releases to a wide array of worldwide business professionals in more than 80 different industries. EIN Presswire also offers affiliate network opportunities and news distribution to tens of thousands of news subscribers daily. Read the newest business news at and the latest world news in more than 80 different industries at